J&J studies find icotrokinra more effective than deucravacitinib for psoriasis

Core Insights - Johnson & Johnson's oral medication, icotrokinra, demonstrated superior effectiveness compared to Bristol Myers' deucravacitinib (Sotyktu) in treating moderate to severe plaque psoriasis based on late-stage study data [2] Company Summary - The late-stage studies indicated that icotrokinra not only met but exceeded the efficacy of the competitor's treatment [2]